NEW YORK, NY--(Marketwire - Mar 11, 2013) - TriMarkPublications.com cites in its newly published "New Oral Anticoagulants Markets" report that the global anticoagulants market will spike to over $24 billion by 2019. For more information, visit: http://www.trimarkpublications.com/new-oral-anticoagulants-markets/.
Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and factor Xa inhibitors. The U.S. anticoagulants market, which encompasses over 60% of the global market for anticoagulants, will grow from $7.06 billion in 2012 to $15.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to once-daily oral anticoagulants.
The "New Oral Anticoagulants Markets" report covers:
- Dabigatran (Pradaxa)
- Rivaroxaban (Xarelto)
- Eliquis (Apixaban)
- Clotting Assays
- Cardiovascular Diseases
- Cardiac Arrhythmia
- Coronary Artery Disease
- Myocardial Infarction
- Heart Valve Replacement
- Deep Vein Thrombosis (DVT)
The "New Oral Anticoagulants Markets" report examines companies manufacturing anticoagulant equipment and supplies in the world. Companies covered include: Akers, Anthera, ARYx, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Eisai, Eli Lilly, Genentech, GlaxoSmithKline, Medicines Company, Medicure, Merck, Novartis, Ortho-McNeil, Pfizer, Pharmion, Portola and Sanofi.
Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/new-oral-anticoagulants-markets/.
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.